New biotech advances RNA therapeutics for rare cardiomyopathies
New biotech advancing RNA therapeutics for rare genetic cardiomyopathies. Lead PRKAG2 program is in phase I/II, with proof-of-concept data expected next year, alongside strategic collaborations and a broader pipeline.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.